# De novo protein design that works reliably

## Specify antibody format

Work with any framework sequence (including known frameworks) or antibody format (mAbs, VH-VL / VHH, etc.).

## Achieve high success rates

Achieve double-digit success rates (>10%) for antibodies and extremely high success rates (>50%) for miniproteins to bypass screening.

## Faster experimentation cycles

Avoid high-throughput screening and go straight to characterization in <2 weeks.

## Prompt with any target

Use public or private structures, or give us the sequence and use a predicted structure.

## Target specific antigen confirmations

Design explicitly for agonism or antagonism by targeting a specific antigen state, which can be difficult to isolate for traditional methods.

## Address challenging targets

Target membrane proteins without the need for lab-based workarounds such as antigen mimetics.

## Design for epitope specificity

Choose an epitope on the target structure, or let the model choose for you. Target small, buried, or non-immunogenic epitopes.

## Handle chemical modifications

Target epitopes with bound ligands or post-translational modifications (PTMs) such as glycans.

## Specify advanced design criteria

Control for species/ortholog specificity or cross-reactivity.

## Commercial use

We are opening up access to Chai-2 to commercial organizations. To schedule a call with our team, fill out the access form and we'll be in touch.

## Academic use

We'll be making Chai-2 available for limited non-commercial use. To register your interest for early access, fill out the access form and we'll be in touch.